Pathios Therapeutics

Pathios Therapeutics Reaches Clinical Milestone with First Patient Dosed in Trial for PTT-4256. We’re thrilled to announce dosing of the first patient in our Phase 1/2 trial for our first-in-class GPR65 small molecule inhibitor PTT-4256, bringing us a step closer to transforming outcomes for people with cancer. Uniquely built on the human genetic understanding of a protective variant, our inhibitor PTT-4256 is designed to reverse immune suppression in the acidic tumor microenvironment, aiming to enhance the immune system’s ability to fight cancer. The RAISIC-1 trial is being conducted in Australia by the team at Pathios Therapeutics Pty Ltd and will assess the safety, tolerability, and early efficacy of PTT-4256 in a broad range of advanced solid tumors, with future modules exploring its potential in specific cancers and combination treatments. Read the full press release to find out more: https://lnkd.in/ewmUvq9a #FirstPatient #GPR65 #immunooncology

This year, Pathios will be the first ever company to inhibit GPR65 in a clinical study. GPR65 is a key component of the tumour-promoting immune cell response. In a small number of cancer patients an inherited reduction in function in GPR65 is linked to a striking increase in survival across multiple cancers. By blocking this receptor with a small molecule, we aim to bring this powerful protective effect to all people with cancer. Our CEO, Paul G Higham, and CSO, Stuart Hughes, will be attending BIO-Europe in Stockholm from November 4-6th. We invite you to connect with Paul and Stuart to hear our compelling rationale for targeting GPR65 and our clinical study due to commence before the end of the year. Reach out to schedule a meeting - we look forward to seeing you there! #BIOEurope2024  

In the lead up to Pathios’ GPR65 antagonist PTT-4256 anticipated start of clinical trials later this year, the team are looking forward to learning more about current and emerging treatment paradigms in priority clinical indications at #ESMO2024 such as Saturday’s session “Evolving Treatment Sequence for Renal Cell Carcinoma” and Sunday's “Systemic Treatment of Anti PD-1 Resistance in Advanced Melanoma”. Reach out if you'd like to discuss the planned PTT-4256 clinical program.

Last week, Innovate UK announced the winners of its Transforming Cancer Therapeutics grant which focuses on developing life-changing cancer treatments. We are delighted to be one of the companies announced as winners! Pathios will use the funding awarded to accelerate development of our unique GPR65 inhibitors as a genetically validated first-in-class immunotherapy for malignant brain tumours.

We are thrilled to announce the appointment of Paul G Higham as our new Chief Executive Officer. With 15 years background in large pharmaceutical companies and over 20 years of C-level executive experience in the biotechnology industry, Paul joins Pathios at a pivotal time as we prepare to initiate clinical development of our first-in-class GPR65 antagonist PTT-4256 in Q4 this year. As we make this transition, our commitment to advancing innovative therapies for cancer remains unwavering and is fuelled by the recently completed first close of $25M in Series B financing.    Paul’s extensive previous experience, including his leadership roles at Valo Therapeutics, Glycotope, and Immatics Biotechnologies, will add significantly to the Pathios team’s ultimate goal of delivering patient benefit. His strategic vision and experience will also be central to our corporate development activities, including our ongoing fundraising efforts to complete our Series B round.    “With an exciting first-in-class therapeutic candidate poised for advancement into first-in-human clinical studies and support from a top-tier investor syndicate of Bristol Myers Squibb, Canaan and Brandon Capital, Pathios is exceptionally well positioned for success. I am delighted to have the opportunity to bring my experience and energy to what is already an exceptional leadership team and help advance the exciting GPR65 antagonist approach at Pathios” said Mr. Higham.    🔗 Learn more about Pathios Therapeutics and our mission to transform cancer therapy: https://lnkd.in/espnJXtD   #Biotech #ImmunoOncology #CancerResearch #Leadership #Innovation #ClinicalTrials #PathiosTherapeutics 

Next week, our Co-founder & Executive Chair, Tom McCarthy, and CSO, Stuart Hughes, will be attending the BIO International Convention 2024 in San Diego. Following our recent Series B first close with Bristol Myers Squibb, we welcome additional investors to connect with us on the opportunity as we continue to advance to the clinic later this year. Connect with Tom or Stuart through the partnering system or at the event to learn more about our innovative approach to cancer immunotherapy through GPR65 inhibition. #Bio2024 #CancerImmunotherapy

Tom McCarthy, Co-founder & Executive Chair of Pathios Therapeutics, will be at the 24th Bio€quity Europe from May 12th-14th. Following our recently announced Series B first close with Bristol Myers Squibb we are seeking additional investors to join us on our journey to the clinic later this year. Connect with Tom through the partneringONE system or at the event to learn more about our unique approach to cancer immunotherapy focused on the inhibition of GPR65, a novel target that has been genetically associated with a range of immunologically-mediated diseases. Pathios is part of the M:M Bio ecosystem, along with Grey Wolf Therapeutics and ThirtyFiveBio who will be joining us at BioEquity. #Bioequity #clinicaltrials #immunotherapy #drugdiscovery #GPR65 #ecosystem

Following the recent announcement of the Series B first close and addition of BMS as a new investor, we're looking forward to presenting details of the GPR65 program at LSX - partnering for Life Science eXecutives on Monday 29th April in London. If you’d like to connect with us at the conference, please find us on the partnering platform, message us on LinkedIn or get in touch via [email protected]

We are delighted to announce the successful USD $25M first close of our Series B financing, and to welcome our new investor Bristol Myers Squibb as we continue to advance PTT-4256 into the clinic later this year. This Series B financing consists of a new strategic investment from Bristol Myers Squibb (BMS), as well as support from existing investors including Canaan and Brandon Capital. Proceeds from the raise will be used for the continued development of Pathios’ unique approach to cancer immunotherapy focused on the inhibition of GPR65, a novel target that has been genetically associated with a range of immunologically-mediated diseases. This investment comes at an exciting inflection point for Pathios as we progress GPR65 inhibitor PTT-4256 towards our first-in-human clinical trial. We'd like to thank the Pathios team and our collaborators for their incredible work, and our investors who continue to believe in our mission to transform cancer outcomes. To find out more, read the full press release here: https://lnkd.in/dp8XmQwX #fundraising #investment #GPR65 #biotech #clinicaltrials #drugdevelopment #immunotherapy #immunooncology

In celebration of this year’s #InternationalWomensDay, we wanted to acknowledge all of the extraordinary women across our ecosystem at M:M Bio, Grey Wolf Therapeutics, Pathios Therapeutics and ThirtyFiveBio who inspire us on our mission. #InspireInclusion #IWD2024